Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,263 across all filing types
Latest filing 2023-07-31 Board/Management Inform…
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Change in Management
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding a change in the role of a senior executive within the company. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events including changes in management. The content specifically announces a management role change, not a full report or financial data. The document length is short (1353 characters), and it is clearly an announcement of management information rather than a detailed report or financial filing. Therefore, the appropriate classification is Board/Management Information (MANG).
2023-07-31 English
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you on the change in role of Mr. Atul Tandon, Business Unit ....
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding a change in the role of a senior executive within the company. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events including changes in management. The content specifically announces a management role change, not a full report or financial data. The document length is short (1353 characters), and it is clearly an announcement of management information rather than a detailed report or financial filing.
2023-07-31 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) notifying them under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. It informs about the receipt of permission from the Drugs Controller General of India for marketing authorization of a new drug indication. The document is short (1420 characters), contains no financial data or detailed report content, and serves as an official announcement of a regulatory approval event. It does not contain financial statements, management discussion, or detailed report data. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2023-07-24 English
This is to inform that AstraZeneca Pharma India Limited has received permission to Import Pharmaceutical Formulations of New Drug for Sale or for Distribution in Form CT-20 (Marketing Authorisation ..
Regulatory Filings Classification · 95% confidence The document is a short notification addressed to stock exchanges (BSE and NSE) regarding AstraZeneca Pharma India Limited receiving permission from the Drugs Controller General of India to import a new drug formulation (Dapagliflozin Tablets 10 mg) for a new indication. It is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, which typically covers material events or information that companies must disclose to the stock exchanges. The document does not contain financial data, earnings, or detailed reports but is an announcement of a regulatory approval event. Given the short length (1420 characters) and the nature of the content, it is a regulatory announcement about a material event. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-07-24 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the loss of share certificates by a shareholder. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, specifically Regulation 39(3), which pertains to share certificate loss and related disclosures. The content is an official notification about a shareholder's lost share certificates, not a financial report, earnings release, or management discussion. It is a regulatory announcement related to shareholding records but does not fit into categories like Major Shareholding Notification (MRQ) since it is about lost certificates, not ownership changes. It is also not a report publication or certification. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-07-22 English
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, we would like to inform you that the Registrar ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the loss of share certificates. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and provides details about the lost share certificates and the shareholders involved. There is no financial data, report content, or management discussion. The document is an announcement related to share certificates, which fits best under the category of Regulatory Filings (RNS) as it is a compliance disclosure to the stock exchanges and does not fit other more specific categories like share issue or director dealings.
2023-07-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.